Your browser doesn't support javascript.
loading
Biochemical diagnosis of mucopolysaccharidosis in a Mexican reference center.
Mendoza-Ruvalcaba, Sandra Del Carmen; Brambila-Tapia, Aniel Jessica Leticia; Juárez-Osuna, Jesús Alejandro; Silva-José, Thiago Donizete Da; García-Ortiz, José Elías.
  • Mendoza-Ruvalcaba SDC; Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica de Occidente, Guadalajara, Jalisco, Mexico.
  • Brambila-Tapia AJL; Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Departamento de Psicología Básica, Guadalajara, Jalisco, Mexico.
  • Juárez-Osuna JA; Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico.
  • Silva-José TDD; Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico.
  • García-Ortiz JE; Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica de Occidente, Guadalajara, Jalisco, Mexico.
Genet Mol Biol ; 43(1): e20180347, 2020.
Article en En | MEDLINE | ID: mdl-32106281
Mucopolysaccharidoses (MPS) are a group of genetic disorders, each resulting from the deficiency of one of the lysosomal enzymes that catabolizes mucopolysaccharides. For the accurate diagnosis of the disease, the quantification of a specific enzymatic activity is needed. In the present study, we analyzed seven MPS over several periods of time ranging from 2 to 5 years in a reference center in Mexico. During this time, a total of 761 samples belonging to 505 individuals with suspected MPS were analyzed. A total of 198 (26.01%) positive results were found. Among these, MPS IVA accounted for the highest frequency of positive results (49.10%), followed by MPS III (17.69%, IIIA: 11.80% and IIIB: 5.89%). Adjusting for the number of births per year, the estimated incidence per 100,000 births for MPS analyzed were as follows: MPS I: 0.19, MPS II: 0.15, MPS IIIA: 0.26, MPS IIIB: 0.13, MPS IVA: 1.10, MPS VI: 0.17 and MPS VII: 0.23, and the combined estimated incidence of MPS was 2.23 per 100,000 births; however, this incidence seems to be highly underestimated when compared with the results of newborn screenings.